%0 Journal Article
%A Teichert, Martin
%A Stumpf, Christine
%A Booken, Nina
%A Wobser, Marion
%A Nashan, Dorothee
%A Hallermann, Christian
%A Mogler, Carolin
%A Müller, Cornelia S L
%A Becker, Jürgen
%A Moritz, Rose K C
%A Andrulis, Mindaugas
%A Nicolay, Jan P
%A Goerdt, Sergij
%A Thomas, Markus
%A Klemke, Claus-Detlev
%A Augustin, Hellmut
%A Felcht, Moritz
%T Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis.
%J Experimental dermatology
%V 24
%N 6
%@ 0906-6705
%C Oxford
%I Wiley-Blackwell
%M DKFZ-2017-03631
%P 424 - 429
%D 2015
%X Primary cutaneous large B-cell lymphomas, leg type (PCLBCL/LT) are primary cutaneous B-cell lymphoma (PCBCL) with an intermediate prognosis. Therefore, antracycline-based polychemotherapy combined with rituximab has been recommended as first-line treatment. Yet, despite this regimen, the 5-year survival rate remains 50-66
%K ANGPT2 protein, human (NLM Chemicals)
%K Angiopoietin-2 (NLM Chemicals)
%K Integrins (NLM Chemicals)
%K Focal Adhesion Protein-Tyrosine Kinases (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:25776770
%R 10.1111/exd.12688
%U https://inrepo02.dkfz.de/record/127608